Compare
ADMA Biologics, Inc. vs Tarsus Pharmaceuticals, Inc. vs Immunocore Holdings plc vs Krystal Biotech, Inc.
| Latest fiscal year | ADMA Biologics, Inc. ADMA | Tarsus Pharmaceuticals, Inc. TARS | Immunocore Holdings plc IMCR | Krystal Biotech, Inc. KRYS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $510.17M | $451.36M | $400.02M | $389.13M |
| Revenue growth (YoY) | +19.6% | +146.7% | +29.0% | +33.9% |
| Gross margin | 57.4% | n/a | n/a | n/a |
| Operating margin | 37.5% | -15.7% | -11.3% | 41.5% |
| Net margin | 28.8% | -14.7% | -8.9% | 52.6% |
| Net income | $146.93M | -$66.42M | -$35.51M | $204.83M |
| EPS (Diluted) | $0.60 | -$1.59 | -$0.71 | $6.84 |
| Operating cash flow | $50.40M | -$12.45M | -$10.71M | $200.87M |
| Free cash flow | $27.82M | -$22.31M | -$15.05M | $188.91M |
| Cash & equivalents | $87.63M | $183.64M | $467.71M | $496.30M |
| Total assets | $624.24M | $562.16M | $1.07B | $1.33B |
| Total liabilities | $146.92M | $218.73M | $686.24M | $114.23M |
| Shareholders' equity | $477.32M | $343.43M | $381.03M | $1.22B |
| Return on year-end equity | 30.8% | -19.3% | -9.3% | 16.8% |
| Shares outstanding | 237.87M | 42.55M | 50.69M | 29.19M |
Revenue, most recent five fiscal years
| Fiscal year | ADMA Biologics, Inc. | Tarsus Pharmaceuticals, Inc. | Immunocore Holdings plc | Krystal Biotech, Inc. |
|---|---|---|---|---|
| Latest | $510.17M Ended 2025-12-31 | $451.36M Ended 2025-12-31 | $400.02M Ended 2025-12-31 | $389.13M Ended 2025-12-31 |
| 1 year earlier | $426.45M Ended 2024-12-31 | $182.95M Ended 2024-12-31 | $310.20M Ended 2024-12-31 | $290.51M Ended 2024-12-31 |
| 2 years earlier | $258.21M Ended 2023-12-31 | $17.45M Ended 2023-12-31 | $249.43M Ended 2023-12-31 | $50.70M Ended 2023-12-31 |
| 3 years earlier | $154.08M Ended 2022-12-31 | $25.82M Ended 2022-12-31 | $174.36M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $80.94M Ended 2021-12-31 | $57.03M Ended 2021-12-31 | $36.48M Ended 2021-12-31 | $0 Ended 2021-12-31 |